Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

l minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay of the webcast will be archived on the Sunesis website for two weeks until March 25, 2008.

About Sunesis' Oncology Programs

Sunesis has built a portfolio of product candidates in oncology focused on inhibition of the cell-cycle and survival signaling. Our lead product candidate, SNS-595, is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double-strand DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 combination with cytarabine in relapsed/refractory AML are both ongoing. SNS-032, a potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory CLL or multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other protein kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information o
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... mathematician (1912-1954), is famous for a number of breakthroughs, ... 1936 he published a paper, which laid the foundation ... a computer algorithm. He next played a pivotal role ... cracked the German military codes, enabling the Allies to ... the late 1940,s he turned his attention to artificial ...
(Date:7/31/2014)... July 31, 2014 According to ... "Quantum Dots Market - Global Industry Analysis, Size, Share, ... was valued at USD 88.5 million in 2011, which ... growing at a CAGR of 53.8% from 2013 to ... Report at  http://www.transparencymarketresearch.com/quantum-dots.html Increasing demand for ...
(Date:7/31/2014)... , July 31, 2014 Research ... "Global Genomics Market 2014-2018" report to their ... Genomics is the study of the genetic material ... be a strong basis for the discovery and development ... human diseases or health conditions. Genomics is supported by ...
(Date:7/31/2014)... Held at the Stanford Cancer Center, the ... the disease and its treatment. Survivors will find information ... as updates on the state-of-the-art with respect to newer ... organizing this educational opportunity,” says KCA CEO Bill Bro, ... colleagues have put together a program that balances the ...
Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... 15 Forest,Laboratories, Inc. (NYSE: FRX ), ... to discuss aclidinium bromide clinical and pre-clinical,data findings ... webcast, which will include a slide presentation and ... 2008 at 9:30am New York time, 3:30pm CET,2:30pm ...
... Israel, May 15 Modigene Inc. (OTC,Bulletin Board: ... develop longer-acting versions of already approved,therapeutic proteins, today ... upcoming Acumen BioFin Rodman & Renshaw 5th Annual ... Central European Summer Time),on May 20, 2008., ...
... MOUNT LAUREL, N.J., May 15 MedQuist ... clinical documentation,workflow technology and services, and StructuRad ... today they have agreed to,integrate and use ... for Radiology(TM) speech recognition solution product., ...
Cached Biology Technology:Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress 2MedQuist and StructuRad Form Partnership to Integrate Report Macros into SpeechQ for Radiology(TM) 2
(Date:7/31/2014)... SHELTON, Conn. , July 31, 2014 /PRNewswire/ ... on the growing m-commerce market, reminds investors and ... generation smart wallet, Wocket™, that it will be on-air ... biometrically secure Wocket smart wallet will be featured ... consumer oriented television show that airs on the ...
(Date:7/30/2014)... Research at New York University is paving the ... damage in civilians and military troops exposed to ... , An article in the current issue ... advancement in detoxifying organophosphates, which are compounds commonly ... process was developed by NYU School of Engineering ...
(Date:7/30/2014)... protected and tended her eggs until they hatched 4.5 ... 2014 in the open-access journal PLOS ONE ... and colleagues. , Octopuses typically have a single reproductive ... take care of their fertilized eggs until they hatch. ... to 3 months, but little is known about the ...
Breaking Biology News(10 mins):NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3Engineering a protein to prevent brain damage from toxic agents 2Deep-sea octopus has longest-known egg-brooding period 2
... vaccine for cattle can effectively reduce levels of E. ... University study has found. The vaccine is also effective using ... help cut costs for the beef industry. David Renter, ... project that researched the effectiveness of products used to prevent ...
... For years, scientists have debated how big a role ... Tree loss is a natural process, but it is ... habitat for many other species. Using high resolution 3-D ... determined tree losses across savannas of Kruger National Park. ...
... Saladax Biomedical, Inc., a privately held company developing ... promise of personalized medicine for new and existing ... existing relationship with Bristol-Myers Squibb Company (NYSE: ... Early Development Collaboration Agreement, which may include multiple ...
Cached Biology News:A new line of defense: Researchers find cattle vaccine works to reduce E. coli O157:H7 2Airborne technology helps manage elephants 2Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb 2
... space and organize gloves, safety glasses, ... are the perfect benchtop storage bins ... processing and manufacturing. Clear static-dissipative PVC ... they attract. Open-slot design for easy ...
... space and organize gloves, safety glasses, ... are the perfect benchtop storage bins ... processing and manufacturing. Clear static-dissipative PVC ... they attract. Many other sizes and ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Mammals microRNA Microarray ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: